Abstract:Abstract Epidermolysis bullosa (EB) comprises a collection of rare skin fragility diseases characterized by mucocutaneous wounding from minimal trauma. For recessive dystrophic EB (RDEB), a paucity of detailed knowledge about symptom presentation, severity and progression throughout life, treatment resource use and costs poses a challenge for delivering robust clinical trials and interpreting RDEB findings. The Prospective EB Longitudinal Evaluation Study (PEBLES) was established to explore the natural history of RDEB and identify potential outcome measures for clinical trial use. This prospective longitudinal observational study was designed to collect comprehensive data from a large cohort of patients with RDEB across all ages recruited from two national UK EB reference centres. Data collection at baseline and annually (≥ 10 year olds) or 6-monthly (< 10 year olds) was wide ranging, including clinical features, laboratory parameters, events occurring in the review period (hospital admissions, squamous cell carcinoma), interventions (hand surgery, oesophageal dilatation), severity and quality of life scores, resource use and socioeconomic costs. Reviews were conducted as face-to-face interviews (virtual reviews during the COVID-19 pandemic), and health records (electronic, paper) were explored to update information since the preceding visit. Screening commenced in November 2014, with 71 UK participants recruited over 9 years (54 adult, 17 child recruits). Their subtypes were RDEB-severe (n = 28), RDEB-intermediate (n = 25), RDEB-inversa (n = 11), RDEB-pruriginosa (n = 6) and RDEB-pretibial (n = 1). They provided 427 reviews, median 7 (range 1–16), with 54 (76%) providing ongoing reviews (median 7 years’ participation); six (8%) died and 11 (15%) withdrew. The preliminary findings were reported as oral and poster conference presentations, with subsequent findings prepared for publication, including itch, wound care costs, pain, quality of life, and milestone events. A steering group monitored study conduct and advised on plans to analyse and disseminate the findings, including future use of an approved repository for findings. To ensure the sustainability of PEBLES and to facilitate expansion to new sites, a REDCap database replaced the original bespoke database. Attempts to expand PEBLES in the UK were unsuccessful, but an expansion team facilitated establishment of two new sites (Austria and Germany), with recruitment to commence early 2024. PEBLES has generated a large number of linked reviews, with publications of important findings regarding itch and costs of wound care and further dissemination planned. PEBLES can be expanded to additional sites, which will increase the participant pool and allow comparison of findings from three countries. Study findings will enable clinicians and researchers to better understand RDEB and variations across subtypes and could form a detailed synthetic control for future RDEB trials.

iscorEB-p: A patient-reported outcome measure for Epidermolysis bullosa. Psychometric properties of the Patient Score from the Instrument for Scoring Clinical Outcome of Research for EB

Translation, cultural adaptation and validation of the German Quality of life in Epidermolysis Bullosa (QOLEB) questionnaire

The psychosocial impact of a chronic disease in Ireland: Burdens and helpful practices for a life with epidermolysis bullosa

Profiling trial burden and patients’ attitudes to improve clinical research in epidermolysis bullosa

Performance of the EULAR Systemic sclerosis Impact of Disease (ScleroID) questionnaire as a patient-reported outcome measure for patients with diffuse systemic sclerosis

SG04 (P104) Developing the Prospective Epidermolysis Bullosa Longitudinal Evaluation Study (PEBLES) to explore natural history and identify endpoints for the rare disease recessive dystrophic epidermolysis bullosa

Patient-reported outcomes and quality of life in recessive dystrophic epidermolysis bullosa: A global cross-sectional survey

P104 Developing the Prospective Epidermolysis Bullosa Longitudinal Evaluation Study (PEBLES) to explore natural history and identify endpoints for the rare disease recessive dystrophic epidermolysis bullosa

Criterion validity and sensitivity to change of the Early Rehabilitation Index (ERI): results from a German multi-center study

Development and content validation of two new patient-reported outcome measures for endometriosis: the Endometriosis Symptom Diary (ESD) and Endometriosis Impact Scale (EIS)

Online, home-based dystrophic epidermolysis bullosa registry

Measurement properties and interpretability of the Patient-Reported Impact of Dermatological Diseases (PRIDD) measure

PS07 (P107) Updating the Assessment of the Psychological and Social Effects of Acne (APSEA) through factor analysis: developing the novel APSEA-3

An Electronic Patient-Reported Outcome Tool for the FACT-B (Functional Assessment of Cancer Therapy-Breast) Questionnaire for Measuring the Health-Related Quality of Life in Patients With Breast Cancer: Reliability Study

Psychometric properties of questionnaires to assess evidence-based practice among occupational, physical and speech therapists: A systematic review

The Eczema Area and Severity Index: An update of progress and challenges in its measurement of atopic dermatitis after 20 years of use

Navigating the diagnostic journey of epidermolysis bullosa – a qualitative study on the lived experiences and needs of parents and patients

Psychometric assessment of the Swedish version of the injustice experience questionnaire among patients with chronic pain

P107 Updating the Assessment of the Psychological and Social Effects of Acne (APSEA) through factor analysis: developing the novel APSEA-3

A biopsychosocial questionnaire for patients with primer Sjögren's syndrome: The BETY-Biopsychosocial Questionnaire

Finalisation and validation of the rheumatoid arthritis impact of disease score, a patient-derived composite measure of impact of rheumatoid arthritis: a EULAR initiative